Thus, H2-GMZ could be inhibiting CFTR channel activity via direct binding and also indirectly through Hsp90, making this drug an especially attractive candidate for ADPKD therapy. The gene discussed is HSP90AB1; the disease is autosomal dominant polycystic kidney disease.